Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock joined Steve Darling with Proactive to bring news the company has engaged the services of Camargo Pharmaceutical services to help navigate the waters of the FDA as they continue with their application for Novel Ivectosol.
Hancock telling Proactive, with the success of pre-clinical studies of their novel solubilized Ivectosol sublingual, FDA approval is the next critical next step in the approval process to support Mountain Valley’s human application objectives.